Articles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Current Editions
Search Archives
BCIQ
Company Profiles
Target Profiles
Product Profiles
Conferences
China Healthcare Summit
Bio€quity Europe
White Papers
Free Trial
/
Subscribe
Sign In
more_vert
Biocentury
Company Profiles
Target Profiles
Product Profiles
Free Trial Information
Export Pdf
Product
Deals
Articles
BioCentury
|
Dec 19, 2020
Management Tracks
RNA pioneer Crooke readies to look beyond Ionis
...20 marketed drugs throughout his career, according to Ionis. Among those, recently launched drugs include Tegsedi
inotersen
...
Read More
BioCentury
|
Sep 15, 2020
Emerging Company Profile
Attralus debuts with $25M series A to tackle systemic amyloidosis
...Spencer Guthrie told BioCentury. Nucleic acid therapies Onpattro patisiran from Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) and Tegsedi
inotersen
...
Read More
BioCentury
|
Aug 31, 2020
Deals
Three years after spinout, Ionis brings back Akcea in $500M acquisition
...future.”By folding Akcea back into itself, Ionis gains full control of two marketed products: Tegsedi
inotersen
...
Read More
BioCentury
|
Aug 8, 2020
Product Development
First oral SMA therapy will be delivered to patients’ homes, well placed for virtual launch
...drugs: Duchenne muscular dystrophy therapies Translarna ataluren and Emflaza deflazacort; hereditary transthyretin amyloidosis treatment Tegesdi
inotersen
...
Read More
BioCentury
|
Nov 13, 2019
Finance
Conjugate company Avidity preps for first dystrophy study with $100M series C
...revealed in September. Akcea gained the approval of two antisense drugs, Waylivra volanesorsen and Tegsedi
inotersen
...
Read More
BioCentury
|
Oct 30, 2019
Financial News
Pfizer surprises Street with Vyndaqel sales, uptake
...Agreement to Differ ”). Ionis Pharmaceuticals Inc. (NASDAQ:IONS) and Akcea Therapeutics Inc. (NASDAQ:AKCA) market Tegsedi
inotersen
...
Read More
BioCentury
|
Oct 7, 2019
Company News
Amid management shakeup, Akcea strikes latest antisense deal
...30. The company reported $10 million in 2Q19 sales of its first approved drug, Tegsedi
inotersen
...
Read More
BioCentury
|
Sep 24, 2019
Company News
Unexpected shakeup at Akcea comes amid drug launches
...“ Ionis Lipid Spinout ”). In March 2018, Ionis also granted Akcea rights to Tegsedi
inotersen
...
...Akcea. Jonathan Block, Associate Editor IONIS-APOCIIIRx, Waylivra, volanesorsen (ISIS 304801, isis-apociiirx, APOC-III antisense inhibitor) Tegsedi,
inotersen
(
IONIS-TTRRx
,
gsk2998728
,
isis-ttrrx
) Onpattro...
Read More
BioCentury
|
Jun 29, 2019
Finance
All eyes on new modality launches, cancer and rare disease data in 3Q19
...$18.0 46% Akcea Therapeutics, Inc. (NASDAQ: AKCA) Spun out of Ionis Pharmaceuticals Inc. (NASDAQ:IONS) Tegsedi
inotersen
...
Read More
BioCentury
|
May 6, 2019
Company News
Pfizer's small molecule tafamidis approved for TTR amyloid cardiomyopathy
...associated with hereditary TTR-mediated amyloidosis (hATTR): Onpattro patisiran from Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) and Tegsedi
inotersen
...
...gained $0.13 to $26.14. Mary Romeo, Staff Writer Onpattro, patisiran (ALN-TTR02, GENZ438027, GZ438027, SAR438027) Tegsedi,
inotersen
(
IONIS-TTRRx
,
gsk2998728
,
isis-ttrrx
) Vyndaqel...
Read More
Items per page:
10
1 - 10 of 87
Previous page
Next page